MRNA Reports earnings results (Ex. 99.1)
Summary
Moderna, Inc. furnished preliminary financial information for the fiscal year ended December 31, 2025, and provided business updates at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 (via Ex. 99.1 press release). The Company expects approximately $1.9 billion in revenue for 2025, an increase of $100 million above the midpoint previously communicated. It also improved its 2025 expected GAAP operating expenses by $200 million and increased its projected year-end cash balance to approximately $8.1 billion. - Reiterates plan for up to 10% revenue growth and GAAP operating expense reductions in 2026. - Anticipates potential first approvals of flu and flu/COVID combination products in 2026. - Expects pivotal trial data readouts in oncology, rare disease, and infectious disease in 2026.
Why It Matters
Investors should note the preliminary 2025 financial results, including the upward revision in revenue and cash balance, and the improved operating expense outlook. The reiterated 2026 revenue growth and operating expense reduction plans, alongside anticipated product approvals and pivotal trial readouts, provide key signals for future performance and pipeline progress.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how MRNA traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View MRNA Charts on TradingViewAffiliate link
Filing Details
Reported Items
Additional Information
- CIK Number
- 0001682852
- Filing Date
- Monday, January 12, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive